Text-only version of this email
Quince Therapeutics
June 25, 2024 7:00 AM EDTQuince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment
of Ataxia-Telangiectasia
View this release →
Or click here to view all releases.
Show all